Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Ladostigil hemitartrate; Ladostigil tartrate; TV-3326

Latest Information Update: 26 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer Avraham Pharmaceuticals
  • Class Antidementias; Carbamates; Indans; Neuroprotectants; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Monoamine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mild cognitive impairment
  • Discontinued Alzheimer's disease

Most Recent Events

  • 26 Aug 2015 Phase-II development for Mild cognitive impairment is ongoing in Austria, Germany and Israel
  • 28 Jul 2015 Interim efficacy data from a phase IIb trial in Mild cognitive impairment released by Avraham Pharmaceuticals
  • 08 Jul 2014 Interim efficacy & adverse events data from a phase IIb trial in Mild cognitive impairment released by Avraham Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top